



The debate brought together experts in law, science, and ethics to discuss evidence, risks, and regulatory models for the therapeutic use of these substances
The DEA has increased the legal quotas for the production of psychedelics such as psilocybin and DMT for 2026, focusing on scientific and medical research in the United States.
Research indicates that psilocybin may offer serenity to end-of-life patients, uniting science, empathy, and a new perspective on dying.
A recent study compiles 28 scientific articles and highlights the main advances and bioethical challenges in the therapeutic use of psychedelics in Brazil, emphasizing the need for regulation, safety, informed consent, and equitable access to therapies.